WASHINGTON, D.C. – Andrew Fish, executive director of AdvaMedDx, and chief strategy officer of AdvaMed, today issued the following statement regarding release of a discussion draft of the Diagnostic Accuracy and Innovation Act (DAIA) in the U.S. House of Representatives:
You are here
Davos-Klosters, Switzerland – AdvaMedDx, the association representing manufacturers of diagnostic tests to promote wellness, improve patient outcomes, and advance public health, today announced a global stakeholder initiative to optimize the use of diagnostic tests in the fight against antimicrobial resistance (AMR). The initiative comes as current trends project antimicrobial resistance could cause up to 10 million deaths annually by 2050.
WASHINGTON, D.C. – Andrew Fish, executive director of AdvaMedDx, today issued the following statement regarding FDA’s decision not to release at this time a final guidance on oversight of laboratory developed tests: